Overview
RXRX market data
Price History
RXRX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.44 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.09 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.77 – $7.18 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.6K · P/B 1.88 · P/S 23.74.
Company News
Generative AI in Drug Discovery: Revolutionizing Pharmaceutical Research and DevelopmentGlobenewswire Inc · Jul 10, 2026, 3:15 PM
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?The Motley Fool · Jul 3, 2026, 4:15 PM
Anthropic Is Going All In on Drug Discovery Just as Pharma Stops Talking About AIBenzinga · Jul 1, 2026, 11:55 AM
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItBenzinga · Jun 16, 2026, 1:15 PM
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · Jun 2, 2026, 10:15 PM
Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5Benzinga · May 14, 2026, 5:23 PM
Global AI in Life Sciences Market Gearing Up for Outstanding Expansion at a CAGR of ~20% by 2034 | DelveInsightGlobenewswire Inc · May 13, 2026, 5:15 PM
8-K filing — RECURSION PHARMACEUTICALS, INC. (RXRX)SEC EDGAR · May 6, 2026, 10:31 AM